<DOC>
	<DOCNO>NCT00155272</DOCNO>
	<brief_summary>This pilot study concomitant radiotherapy thalidomide patient locally advance HCC.Besides toxicity efficacy , mechanistic study include dynamic contrast enhance MRI serum cytokine evaluate .</brief_summary>
	<brief_title>Radiotherapy Plus Thalidomide Locally Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>This pilot study concomitant radiotherapy thalidomide patient locally advanced HCC . Patients whose tumor ( ) suitable local treatment , surgery , trans-arterial chemoembolization ( TAE ) , ethanol injection , radiofrequency ablation . enrolled.Radical radiotherapy start pre-treatment evaluation . The total dose RT 50Gy 25 fraction local tumor ( ) . Oral Thalidomide start 3 day RT begin . Thalidomide treatment continue totally 6 month tumor progression . Dynamic contrast enhance MRI ( DCEMRI ) do follow time point assess change tumor perfusion : ( 1 ) start thalidomide treatment ; ( 2 ) 3 day thalidomide radiotherapy ; ( 3 ) 2weeks radiotherapy begin ; ( 4 ) 1 month radiotherapy complete . DCEMRI do every 3 month disease progression.Serum sample angiogenic cytokine study also collected.The study design evaluate feasibility tolerability combination treatment radiotherapy thalidomide locally advanced HCC . The sample size determine expect incidence grade 4 toxicity combination treatment versus radiotherapy alone locally advanced HCC . Since grade 4 toxicity radiotherapy alone 7-9 % , need least 15 patient evaluate feasibility combination treatment . With estimate drop rate approximately 10 % , 17 patient enrol .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1.1 Patients measurable , locally advanced HCC suitable local therapy , include surgery , TAE , alcohol injection , radiofrequency ablation . 1.2 Patients histological confirm HCC patient histological diagnosis meet follow criterion : 1.2.1 Presence chronic viral hepatitis and/or cirrhosis 1.2.2 Presence hepatic tumor ( ) image finding ( sonography , CT scan ) compatible HCC . 1.2.3 A persistent elevation serum afetoprotein level ³ 400 ng/ml without evidence anafetoproteinsecreting germ cell tumor . 1.3 Patients without local systemic therapy HCC within 4 week . 1.4 Patients age &gt; 20 year &lt; 70 year . 1.5 Patients performance status ECOG score &lt; 1 . 1.6 Patients must fulfill follow criterion : 1.6.1 ChildPugh ’ Score ≦ 7 . 1.6.2 Serum total bilirubin &lt; 1.5 time upper normal limit ( UNL 1.6.3 Serum alanine transaminase ( ALT ) &lt; 5 time UNL 1.6.4 Platelet count &gt; 5.0 x 104 / mm3 . 1.6.5 White blood cell count &gt; 3,000 / mm3 . 1.6.6 Serum creatinine &lt; 2.0 mg/dL 1.7 Patient must local tumor le one half whole liver tumor encompass within RT field 1.8 Signed inform consent 1.9 Sexually active patient , conjunction partner , must practice birth control , 2 month , thalidomide therapy . 1.10 Female patient childbearing age must negative pregnancy test . 2.1 . Patients document extrahepatic metastasis . 2.2 . Patients receive previous radiotherapy abdominal area . 2.3 . Patients receive thalidomide treatment prior enrollment . 2.4 . Patients investigational drug treatment within 4 week prior enrollment . 2.5 . Patients NCI grade 2 great peripheral neuropathy cause . 2.6 . Patients systemic disease require concurrent usage glucocorticosteroid immunosuppressant agent ( ) . 2.7 . Patients major systemic disease attend physician consider inappropriate radiotherapy thalidomide therapy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Dynamic contrast enhance MRI</keyword>
</DOC>